It was also found that PUM1 can positively regulate (DDX5) and increase cell viability, thus proving that the downregulation of PUM1 and DDX5 can reduce tumor cell viability and is a therapeutic target for the increased sensitivity of colon cancer to trastuzumab (13). The gene discussed is PUM1; the disease is neoplasm.